Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Wednesday, July 22, 2026 1 min read
Key Takeaway: Dexcom has been selected as the first participant in the FDA's TEMPO Pilot Program, which aims to assess innovative digital health technologies for chronic disease management. This initiative is designed to generate real-world evidence to support the effectiveness of these technologies. Dexcom's involvement marks a significant step in advancing digital health solutions.
Market Sentiment Analysis
POSITIVE FACTORS
Dexcom is the first company selected for the FDA's TEMPO program.
The initiative aims to evaluate innovative digital health technologies.
Participation will enhance chronic disease management.
It will generate real-world evidence for health technologies.
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom
Frequently Asked Questions
What is the TEMPO Pilot Program?
The TEMPO Pilot Program is an FDA initiative to evaluate digital health technologies for chronic disease management.
Why was Dexcom selected for the TEMPO program?
Dexcom was chosen as the first participant due to its leadership in glucose biosensing and innovative technologies.
What will Dexcom's participation involve?
Dexcom's participation will focus on improving chronic disease management and generating real-world evidence.
What is the significance of this selection?
Being the first selected participant highlights Dexcom's role in advancing digital health solutions.